Journal of Gastrointestinal Surgery

, Volume 17, Issue 1, pp 94–101 | Cite as

Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study

  • Jeffrey M. Hardacre
  • Mary Mulcahy
  • William Small
  • Mark Talamonti
  • Jennifer Obel
  • Smitha Krishnamurthi
  • Caio S. Rocha-Lima
  • Howard Safran
  • Heinz-Joseph Lenz
  • E. Gabriela Chiorean
2012 SSAT Plenary Presentation



Despite continued investigation, limited progress has been made in the adjuvant treatment of resected pancreatic cancer. Novel or targeted therapies are needed.


Multi-institutional, open-label, dose-finding, phase 2 trial evaluating the use of algenpantucel-L (NewLink Genetics Corporation, Ames, IA) immunotherapy in addition to chemotherapy and chemoradiotherapy in the adjuvant setting for resected pancreatic cancer ( identifier, NCT00569387). The primary outcome was 12-month disease-free survival. Secondary outcomes included overall survival and toxicity.


Seventy patients were treated with gemcitabine and 5-fluorouracil-based chemoradiotherapy as well as algenpantucel-L (mean 12 doses, range 1–14). After a median follow-up of 21 months, the 12-month disease-free survival was 62 %, and the 12-month overall survival was 86 %. The most common adverse events were injection site pain and induration.


The addition of algenpantucel-L to standard adjuvant therapy for resected pancreatic cancer may improve survival. A multi-institutional, phase 3 study is ongoing ( identifier, NCT01072981).


Pancreatic cancer Adjuvant therapy Immunotherapy 



  1. 1.
    Kalser MH, Ellenber SS. Pancreatic Cancer: Adjuvant Combined Radiation and Chemotherapy Following Curative Resection. Arch Surg 1985;120:899–903.PubMedCrossRefGoogle Scholar
  2. 2.
    Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant Radiotherapy and 5-fluorouracil after Curative Resection of Cancer of the Pancreas and Periampullary Region: Phase III Trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999;230:776–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant Chemoradiotherapy and Chemotherapy in Resectable Pancreas Cancer: A Randomised Controlled Trial. Lancet 2001;358:1576–1585.PubMedCrossRefGoogle Scholar
  4. 4.
    Oettle H, Post S, Neuhaus P, et al. Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients Undergoing Curative-intent Resection of Pancreatic Cancer: A Randomized Controlled Trial. JAMA 2007;297:267–77.PubMedCrossRefGoogle Scholar
  5. 5.
    Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs. Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A Randomized Controlled Trial. JAMA 2008;299:1019–26.PubMedCrossRefGoogle Scholar
  6. 6.
    Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant Chemotherapy with Fluorouracil plus Folinic Acid vs. Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial. JAMA 2010;304:1073–81.PubMedCrossRefGoogle Scholar
  7. 7.
    National Comprehensive Cancer Network Guidelines Version 2.2012—Pancreatic Adenocarcinoma. Available at: Accessed 15 March 2012
  8. 8.
    Joziasse DH, Oriol R. Xenotransplantation: the Importance of the Galα1,3Gal Epitope in Hyperacute Vascular Rejection. Biochim Biophy Acta 1999;1455:403–18.CrossRefGoogle Scholar
  9. 9.
    Galili U, Mandrell RE, Hamadeh RM, et al. Interaction between Human Natural Anti-alpha-galactosyl Immunoglobulin G and Bacteria of the Human Flora. Infect Immun 1988;56:1730–37.PubMedGoogle Scholar
  10. 10.
    Baumann BC, Forte P, Hawley RJ, et al. Lack of Galactose-α-1,3-galactose Expression on Porcine Endothelial Cells Prevents Complement-induced Lysis but not Direct Xenogenic NK Cytotoxicity. J Immunol 2004;172:6460–7.PubMedGoogle Scholar
  11. 11.
    Schaapherder AF, Daha MR, te Bulte MT, et al. Antibody-dependent cell-mediated cytotoxicity against porcine endothelium induced by a majority of human sera. Transplantation 1994;57:1376–82.PubMedCrossRefGoogle Scholar
  12. 12.
    Watier H, Guillaumin JM, Vallee I, et al. Human NK cell-mediated direct and IG-dependent Cytotoxicity against Xenogeneic Porcine Epithelial Cells. Transpl Immunol 1996;4:293–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Watier H, Giollaumin JM, Piller F, et al. Removal of Terminal α-galactosyl Residues from Xenogeneic Porcine Endothelial Cells. Decrease in Complement-mediated cytotoxicity but Persistence of IgG1-mediated Antibody-dependent Cell-mediated Cytotoxicity. Transplantation 1996;62:105–13.PubMedCrossRefGoogle Scholar
  14. 14.
    Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th Edition AJCC Pancreatic Cancer Staging System: Report from the National Cancer Database. Cancer 2007;110:738–44.PubMedCrossRefGoogle Scholar
  15. 15.
    Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic Nomogram for Patients Undergoing Resection for Adenocarcinoma of the Pancreas. Ann Surg 2004;240:293–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Zitvogel L, Apetoh L, Ghiringhelli F, et al. The Anticancer Immune Response: Indispensable for Therapeutic Success? J Clin Invest 2008;118:1991–2001.PubMedCrossRefGoogle Scholar
  17. 17.
    Lutz E, Yeo CJ, Lillemoe KD, et al. A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation. Ann Surg 2011;253:328–35.PubMedCrossRefGoogle Scholar
  18. 18.
    Abou-Alfa GK, Chapman PB, Feilchenfeldt J, et al. Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine. Am J Clin Oncol 2011;34:321–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Morse MA, Nair SK, Boczkowski D, et al. The Feasibility and Safety of Immunotherapy with Dendritic Cells Loaded with CEA mRNA Following Neoadjuvant Chemoradiotherapy and Resection of Pancreatic Cancer. Int J Gastrointest Cancer 2002;32:1–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Ramanathan RK, Lee KM, McKolanis J, et al. Phase I Study of a MUC1 Vaccine Composed of Different Doses of MUC1 Peptide with SB-A2 Adjuvant in Resected and Locally Advanced Pancreatic Cancer. Cancer Immunol Immunother 2005;54:254–64.PubMedCrossRefGoogle Scholar
  21. 21.
    Maki RG, Livingston PO, Lewis JJ, et al. A Phase I Pilot Study of Autologous Heat Shock Protein Vaccine HXPPC-96 in Patients with Resected Pancreatic Adenocarcinoma. Dig Dis Sci 2007;52:1964–72.PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2012

Authors and Affiliations

  • Jeffrey M. Hardacre
    • 1
  • Mary Mulcahy
    • 2
  • William Small
    • 2
  • Mark Talamonti
    • 3
  • Jennifer Obel
    • 3
  • Smitha Krishnamurthi
    • 4
  • Caio S. Rocha-Lima
    • 5
  • Howard Safran
    • 6
  • Heinz-Joseph Lenz
    • 7
  • E. Gabriela Chiorean
    • 8
  1. 1.Department of SurgeryUniversity Hospitals Seidman Cancer Center and Case Western Reserve UniversityClevelandUSA
  2. 2.Northwestern UniversityChicagoUSA
  3. 3.Northshore University Health SystemEvanstonUSA
  4. 4.Department of MedicineUniversity Hospitals Seidman Cancer Center and Case Western Reserve UniversityClevelandUSA
  5. 5.University of MiamiMiamiUSA
  6. 6.Brown UniversityProvidenceUSA
  7. 7.University of Southern CaliforniaLos AngelesUSA
  8. 8.Indiana University Melvin and Bren Simon Cancer CenterIndianapolisUSA

Personalised recommendations